Reports

Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.

Global Peripheral Neuropathy Treatment Market Share, Size, Growth, Trends, Forecast, Analysis: By Type: Diabetic Peripheral Neuropathy, Chemotherapy-Induced Peripheral Neuropathy, Idiopathic Peripheral Neuropathy, Others; By Therapeutics Method; By End User; By Treatment Channel; Regional Analysis; Supplier Landscape; 2023-2031

Global Peripheral Neuropathy Treatment Market Outlook

The global peripheral neuropathy treatment market reached a value of about USD 737 million in 2022 and is expected to grow at a CAGR of 3.7% during the forecast period of 2023-2031. With the rising prevalence of chronic diseases, which increase the risk of peripheral neuropathy in chronic disease patients, the market is expected to reach USD 1022 million by 2031. 

 

Peripheral Neuropathy Treatment Market Insights

Peripheral neuropathy is a catch-all term for nerve diseases that affect a specific part of the nervous system. Peripheral neuropathy occurs when the nerves are damaged or destroyed and no longer functioning properly. This interferes with the normal functioning of the nerves. They may send pain signals when there is nothing causing pain, or they may not send a pain signal even if something is causing the pain. This could be because of systemic illness, infection, injury, an inherited disorder hormonal imbalance, certain medications, or vitamin deficiency.

 

Anyone, regardless of age, gender, race or ethnicity, personal circumstances, medical history, or other factors, can develop peripheral neuropathy. However, some people are predisposed to certain types of peripheral neuropathy. Some age-related diseases are also associated with peripheral neuropathy. As a result, the risk of developing peripheral neuropathy rises with age.

 

In the body, there are three types of nerves. Doctors will diagnose the type of peripheral neuropathy based on the group of nerves that it affects. The three groups are as follows: 

 

  • Motor: These nerves control muscle movements, such as walking, talking, or using the hands or arms.
  • Sensory: These are in charge of sensory information, such as hot or cold, pain, or touch.
  • Autonomic: These are in charge of non-visible body processes, such as breathing, heartbeat, and digestion.

 

Peripheral neuropathy is usually diagnosed using a combination of methods. Some of the examples are:

  • Examinations of the blood (these can detect many problems, ranging from immune system problems to toxins and poisons, especially metals like mercury or lead)
  • Electromyogram
  • Ultrasound of the nerves
  • Biopsy of a nerve
  • Genetic analysis
  • Magnetic resonance imaging (MRI)

 

According to the peripheral neuropathy treatment market research report, the market can be categorised into the following segments:

 

Market Breakup by Type

  • Diabetic Peripheral Neuropathy
  • Chemotherapy-Induced Peripheral Neuropathy
  • Idiopathic Peripheral Neuropathy
  • HIV/AIDS Associated Peripheral Neuropathy

 

Market Breakup by Treatment Method

  • Pharmacological Therapies
    • Pain Relievers
    • Anti-Seizure Medications
    • Anti-Depressants
  • Non-Pharmacological Therapies
    • Transcutaneous Electrical Nerve Stimulation
    • Plasma Exchange
    • Others
  • Others

 

Peripheral Neuropathy Treatment Market Breakup by End User

  • Hospitals and Clinics
  • Retail Pharmacy
  • Online Pharmacy

 

Market Breakup by Treatment Channel

  • Public
  • Private

 

Market Breakup by Region

  • North America
    • United States of America
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others

 

Peripheral Neuropathy Epidemiology

Peripheral neuropathy is common because it refers to so many different conditions. Peripheral neuropathy affects approximately 2.4% of the world's population. That percentage rises to between 5% and 7% among people aged 45 and above. Peripheral neuropathy affects approximately 2.4% of the population. In older populations, the prevalence rises to 8%. 

 

Peripheral neuropathy can be a symptom of a variety of pathologies that require further investigation and/or treatment. Furthermore, peripheral neuropathies must be treated before they cause complications, such as falls that result in hip fractures or pedal infections that necessitate amputation.

 

Global Peripheral Neuropathy Therapeutic Landscape

Peripheral neuropathy treatment can vary greatly depending on the cause. In general, the following methods of treatment are more commonly used for peripheral neuropathy:

 

Medications: Many medications are available to treat peripheral nervous system issues. Injections, pills taken by mouth, patches that stick to the skin, slow-release medication, and other options are available.

 

Surgery: Surgery can help reconnect severed nerves and alleviate pain caused by trapped nerves. It can also cut or remove damaged or malfunctioning nerves, preventing signals from reaching the brain and vice versa.

 

Physical Therapy: This can assist in recovering from injuries or medical procedures, as well as improving pain symptoms. It can also help adapt to changes in the nervous system, such as improving balance and preventing falls.

 

Wearable Devices and Equipment: These include medical devices such as braces, canes, and walkers, and prescribed footwear. These do not treat peripheral neuropathy directly, but they can help prevent complications. One example is special footwear for people with Type 2 diabetes who have peripheral neuropathy.

 

If standard medications do not relieve the pain from peripheral neuropathy or nerve injury, pain specialists may occasionally recommend alternative treatments, such as acupuncture, transcutaneous electrical nerve stimulation, injections, or surgery to implant a spinal cord stimulator.

 

Global Peripheral Neuropathy Market Drivers and Restraint

The rising prevalence of chronic diseases such as diabetes, cancer, and hypothyroidism, which increase the risk of peripheral neuropathy in chronic disease patients, and rising cancer prevalence is expected to drive the global peripheral neuropathy treatment market growth over the forecast period.

 

High product costs and the availability of alternative treatments, as well as stringent regulatory compliance and device recalls, are major factors impeding growth in the global market. The rising cost of drugs used in the treatment of peripheral neuropathy and the increasing availability of alternative therapies for the treatment of peripheral neuropathy, are some of the factors constraining the market growth.

 

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the global peripheral neuropathy treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:  

 

  • Abbott Laboratories
  • Bristol Myers Squibb Co
  • Novartis AG
  • Eli Lilly and Company
  • Pfizer Inc.
  • GlaxoSmithKline Plc
  • Merck and Co. Inc.
  • F. Hoffmann-La Roche Ltd
  • Cipla Ltd.
  • Lupin Ltd
  • Dr. Reddy’s Laboratories
  • RxFunction, Inc.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2022
Historical Period 2018-2022
Forecast Period 2023-2031
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Type
  • Therapeutics Method
  • End User
  • Treatment Channel
  • Region
Breakup by Type
  • Diabetic Peripheral Neuropathy
  • Chemotherapy-Induced Peripheral Neuropathy
  • Idiopathic Peripheral Neuropathy
  • HIV/AIDS Associated Peripheral Neuropathy
Breakup by Therapeutics Method
  • Pharmacological Therapies
  • Non-Pharmacological Therapies
  • Others
Breakup by End User
  • Hospitals And Clinics
  • Retail Pharmacy
  • Online Pharmacy
Breakup by Treatment Channel
  • Public
  • Private
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • SWOT
  • Porter's Five Forces
  • Key Indicators for Demand
  • Key Indicators for Price
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Abbott Laboratories
  • Bristol Myers Squibb Co
  • Novartis AG
  • Eli Lilly and Company
  • Pfizer Inc.
  • GlaxoSmithKline Plc
  • Merck and Co. Inc.
  • F. Hoffmann-La Roche Ltd
  • Cipla Ltd.
  • Lupin Ltd
  • Dr. Reddy’s Laboratories
  • RxFunction, Inc.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
        1.1.1    Research Objectives
        1.1.2    Key Findings of the Report
    1.2    Limitations of the Study and Scope for Future Research
2    Research Methodology
3    Executive Summary
4    Global Peripheral Neuropathy Overview 

    4.1    Guidelines and Stages
    4.2    Pathophysiology
    4.3    Screening and Diagnosis
    4.4    Treatment Pathway 
5    Patient Profile
    5.1    Patient Profile Overview 
    5.2    Patient Psychology and Emotional Impact Factors
    5.3    Risk Assessment and Treatment Success Rate
6    Global Peripheral Neuropathy Treatment Market
    6.1    Global Peripheral Neuropathy Treatment Market Overview
    6.2    Global Peripheral Neuropathy Treatment Market Analysis 
        6.2.1    Market Overview
            6.2.1.1    Global Peripheral Neuropathy Treatment Market Historical Value (2016-2022) 
            6.2.1.2    Global Peripheral Neuropathy Treatment Market Forecast Value (2023-2031)
    6.3    Global Peripheral Neuropathy Treatment Market by Type
        6.3.1    Market Overview
            6.3.1.1    Diabetic Peripheral Neuropathy
            6.3.1.2    Chemotherapy-Induced Peripheral Neuropathy 
            6.3.1.3    Idiopathic Peripheral Neuropathy 
            6.3.1.4    HIV/AIDS Associated Peripheral Neuropathy
    6.4    Global Peripheral Neuropathy Treatment Market by Therapeutics Method
        6.4.1    Market Overview
            6.4.1.1    Pharmacological Therapies
                6.4.1.1.1    Pain Relievers 
                6.4.1.1.2    Anti-Seizure Medications 
                6.4.1.1.3    Anti-Depressants
            6.4.1.2    Non-Pharmacological Therapies
                6.4.1.2.1    Transcutaneous Electrical Nerve Stimulation 
                6.4.1.2.2    Plasma Exchange 
                6.4.1.2.3    Others
            6.4.1.3    Others
    6.5    Global Peripheral Neuropathy Treatment Market by End User
        6.5.1    Market Overview
            6.5.1.1    Hospitals And Clinics 
            6.5.1.2    Retail Pharmacy 
            6.5.1.3    Online Pharmacy
    6.6    Global Peripheral Neuropathy Treatment Market by Treatment Channel
        6.6.1    Public
        6.6.2    Private
    6.7    Global Peripheral Neuropathy Treatment Market by Region
        6.7.1    Market Overview
            6.7.1.1    North America 
                6.7.1.1.1    Historical Trend (2016-2022)
                6.7.1.1.2    Forecast Trend (2023-2031)
            6.7.1.2    Europe
                6.7.1.2.1    Historical Trend (2016-2022)
                6.7.1.2.2    Forecast Trend (2023-2031)
            6.7.1.3    Asia Pacific
                6.7.1.3.1    Historical Trend (2016-2022)
                6.7.1.3.2    Forecast Trend (2023-2031)
            6.7.1.4    Latin America
                6.7.1.4.1    Historical Trend (2016-2022)
                6.7.1.4.2    Forecast Trend (2023-2031)
            6.7.1.5    Middle East and Africa
                6.7.1.5.1     Historical Trend (2016-2022)
                6.7.1.5.2    Forecast Trend (2023-2031)
7    North America Peripheral Neuropathy Treatment by Treatment Market
    7.1    United States of America
        7.1.1    Historical Trend (2016-2022)
        7.1.2    Forecast Trend (2023-2031)
    7.2    Canada 
        7.2.1    Historical Trend (2016-2022)
        7.2.2    Forecast Trend (2023-2031)
8    Europe Peripheral Neuropathy Treatment by Treatment Market
    8.1    United Kingdom
        8.1.1    Historical Trend (2016-2022)
        8.1.2    Forecast Trend (2023-2031)
    8.2    Germany
        8.2.1    Historical Trend (2016-2022)
        8.2.2    Forecast Trend (2023-2031)
    8.3    France
        8.3.1    Historical Trend (2016-2022)
        8.3.2    Forecast Trend (2023-2031)
    8.4    Italy
        8.4.1    Historical Trend (2016-2022)
        8.4.2    Forecast Trend (2023-2031)
9    Asia Pacific Peripheral Neuropathy Treatment by Treatment Market
    9.1    China
        9.1.1    Historical Trend (2016-2022)
        9.1.2    Forecast Trend (2023-2031)
    9.2    Japan
        9.2.1    Historical Trend (2016-2022)
        9.2.2    Forecast Trend (2023-2031)
    9.3    India
        9.3.1    Historical Trend (2016-2022)
        9.3.2    Forecast Trend (2023-2031)
    9.4    ASEAN
        9.4.1    Historical Trend (2016-2022)
        9.4.2    Forecast Trend (2023-2031)
    9.5    Australia
        9.5.1    Historical Trend (2016-2022)
        9.5.2    Forecast Trend (2023-2031)
10    Latin America Peripheral Neuropathy Treatment by Treatment Market
    10.1    Brazil
        10.1.1    Historical Trend (2016-2022)
        10.1.2    Forecast Trend (2023-2031)
    10.2    Argentina
        10.2.1    Historical Trend (2016-2022)
        10.2.2    Forecast Trend (2023-2031)
    10.3    Mexico
        10.3.1    Historical Trend (2016-2022)
        10.3.2    Forecast Trend (2023-2031)
11    Middle East and Africa Peripheral Neuropathy Treatment by Treatment Market
    11.1    Saudi Arabia
        11.1.1    Historical Trend (2016-2022)
        11.1.2    Forecast Trend (2023-2031)
    11.2    United Arab Emirates
        11.2.1    Historical Trend (2016-2022)
        11.2.2    Forecast Trend (2023-2031)
    11.3    Nigeria
        11.3.1    Historical Trend (2016-2022)
        11.3.2    Forecast Trend (2023-2031)
    11.4    South Africa
        11.4.1    Historical Trend (2016-2022)
        11.4.2    Forecast Trend (2023-2031)
12    Current Scenario Evaluation and Regulatory Framework
    12.1    Emerging Therapies and Clinical Trials Synopsis
    12.2    Patent Landscape
        12.2.1    Patent Overview
            12.2.1.1    Patent Status and Expiry
            12.2.1.2    Timelines from Drug Development to Commercial Launch
            12.2.1.3    New Drug Application
                12.2.1.3.1    Documentation and Approval Process
    12.3    Cost of Treatment
    12.4    Regulatory Framework
        12.4.1    Regulatory Overview
            12.4.1.1    US FDA
            12.4.1.2    EU EMA
            12.4.1.3    INDIA CDSCO
            12.4.1.4    JAPAN PMDA
            12.4.1.5    Others
13    Challenges and Unmet Needs
    13.1    Treatment Pathway Challenges
    13.2    Compliance and Drop-Out Analysis
    13.3    Awareness and Prevention Gaps
14    Global Peripheral Neuropathy Treatment Market Dynamics
    14.1    Market Drivers and Constraints
    14.2    SWOT Analysis
    14.3    Porter’s Five Forces Model
    14.4    Key Demand Indicators
    14.5    Key Price Indicators 
    14.6    Industry Events, Initiatives and Trends  
    14.7    Value Chain Analysis
15    Supplier Landscape
    15.1    Abbott Laboratories
        15.1.1    Company Overview
        15.1.2    Product Portfolio
        15.1.3    Demographic Reach and Achievements
        15.1.4    Mergers and Acquisitions
        15.1.5    Certifications
    15.2    Bristol Myers Squibb Co
        15.2.1    Company Overview
        15.2.2    Product Portfolio
        15.2.3    Demographic Reach and Achievements
        15.2.4    Mergers and Acquisitions
        15.2.5    Certifications
    15.3    Novartis AG
        15.3.1    Company Overview
        15.3.2    Product Portfolio
        15.3.3    Demographic Reach and Achievements
        15.3.4    Mergers and Acquisitions
        15.3.5    Certifications
    15.4    Eli Lilly and Company
        15.4.1    Company Overview
        15.4.2    Product Portfolio
        15.4.3    Demographic Reach and Achievements
        15.4.4    Mergers and Acquisitions
        15.4.5    Certifications
    15.5    Pfizer Inc.
        15.5.1    Company Overview
        15.5.2    Product Portfolio
        15.5.3    Demographic Reach and Achievements
        15.5.4    Mergers and Acquisitions
        15.5.5    Certifications
    15.6    GlaxoSmithKline Plc
        15.6.1    Company Overview
        15.6.2    Product Portfolio
        15.6.3    Demographic Reach and Achievements
        15.6.4    Mergers and Acquisitions
        15.6.5    Certifications 
    15.7    Merck and Co. Inc.
        15.7.1    Company Overview
        15.7.2    Product Portfolio
        15.7.3    Demographic Reach and Achievements
        15.7.4    Mergers and Acquisitions
        15.7.5    Certifications 
    15.8    F. Hoffmann-La Roche Ltd
        15.8.1    Company Overview
        15.8.2    Product Portfolio
        15.8.3    Demographic Reach and Achievements
        15.8.4    Mergers and Acquisitions
        15.8.5    Certifications
    15.9    Cipla Ltd.
        15.9.1    Company Overview
        15.9.2    Product Portfolio
        15.9.3    Demographic Reach and Achievements
        15.9.4    Mergers and Acquisitions
        15.9.5    Certifications
    15.10    Lupin Ltd
        15.10.1    Company Overview
        15.10.2    Product Portfolio
        15.10.3    Demographic Reach and Achievements
        15.10.4    Mergers and Acquisitions
        15.10.5    Certifications 
    15.11    Dr. Reddy’s Laboratories
        15.11.1    Company Overview
        15.11.2    Product Portfolio
        15.11.3    Demographic Reach and Achievements
        15.11.4    Mergers and Acquisitions
        15.11.5    Certifications 
    15.12    RxFunction, Inc. 
        15.12.1    Company Overview
        15.12.2    Product Portfolio
        15.12.3    Demographic Reach and Achievements
        15.12.4    Mergers and Acquisitions
        15.12.5    Certifications
16    Recommendations and Discussion
17    Global Peripheral Neuropathy Treatment Drugs Distribution Model (Additional Insight)

    17.1    Overview 
    17.2    Potential Distributors 
    17.3    Key Parameters for Distribution Partner Assessment 
18    Payment Methods (Additional Insight)
    18.1    Government Funded
    18.2    Private Insurance
    18.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The market attained a value of USD 737 million in 2022.

The market is likely to grow at a CAGR of 3.7% during the forecast period of 2023-2031.

The market is expected to reach a value of USD 1022 million by 2031.

The rising prevalence of chronic diseases, such as diabetes, cancer, and hypothyroidism, increases the risk of peripheral neuropathy in chronic disease patients.

The major regional markets include North America, Europe, Latin America, Middle East and Africa, and Asia Pacific.

The major types include diabetic, chemotherapy-induced, idiopathic, and HIV/AIDS associated peripheral neuropathy.

The key players in the market include Abbott Laboratories, Bristol Myers Squibb Co, Novartis AG, Eli Lilly and Company, Pfizer Inc., GlaxoSmithKline Plc, Merck and Co. Inc., F. Hoffmann-La Roche Ltd, Cipla Ltd., Lupin Ltd, Dr. Reddy’s Laboratories, and RxFunction, Inc., among others.

High product costs, availability of alternative treatments, and stringent regulatory compliance and device recalls, are major factors impeding the market growth.

Purchase Full Report

Mini Report

$2499
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$6499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$7999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER